In 2003 worldwide sales of allergic rhinitis nasal sprays alone were valued at US$2.4B (IMS, Valois), up from 2002 worldwide sales of all over-the-counter (OTC) nasal sprays except steroids, estimated at US$820M (IMS, Valois). That’s a significant amount of drug administered via the nose every year (Figure 1). With a 2004 projection in the range of US$3.5-4B in sales, this is not a sector to be sniffed at.
In 2003 worldwide sales of allergic rhinitis nasal sprays alone were valued at US$2.4B (IMS, Valois), up from 2002 worldwide sales of all over-the-counter (OTC) nasal sprays except steroids, estimated at US$820M (IMS, Valois). That’s a significant amount of drug administered via the nose every year (Figure 1). With a 2004 projection in the range of US$3.5-4B in sales, this is not a sector to be sniffed at.
In 2003 worldwide sales of allergic rhinitis nasal sprays alone were valued at US$2.4B (IMS, Valois), up from 2002 worldwide sales of all over-the-counter (OTC) nasal sprays except steroids, estimated at US$820M (IMS, Valois). That’s a significant amount of drug administered via the nose every year (Figure 1). With a 2004 projection in the range of US$3.5-4B in sales, this is not a sector to be sniffed at.
Historically, nasal therapy has focused on the provision of low cost, over the counter, local treatments for nasal allergy and congestion. However, emerging interest in using the nose as a gateway into the blood stream, immune system and even directly into the brain has sparked development of new opportunities, companies and products. While once-daily tablets and capsules remain the drug delivery vehicle of choice, they are sometimes impractical. Acid or enzyme degradation, or a simple inability to penetrate the gastrointestinal mucosa, force the owners of promising new vaccines, bio-molecules or fragile small molecules to seek an alternative way into the body. If the molecule has to act quickly to be effective, but its indication does not justify injection, most companies with molecules that are unstable or incapable of being absorbed sooner or later look at nasal or pulmonary delivery.
While pulmonary drug delivery accounts for a larger share of the pharmaceutical market (as there are more products and most are prescription only, not OTC) and certainly dominates research into aerosol-based delivery systems, there are compelling reasons for a company to attempt development of a nasal product. (Table 1) Whatever the reason, the range of approved nasally administered drugs is increasing and there are some interesting possibilities in the pipeline. The ability of nasally administered drugs to be absorbed into the blood stream is established in humans, and sumatriptan, calcitonin, desmopressin, nicotine and several other agents are commercially available. To be a candidate for this route, doses must be small and the drug absorbed before a combination of mechanical and ciliary clearance mechanisms remove it. Strategies to increase efficacy range from increased viscosity of sprayed formulations or bioadhesives to slow ciliary transport and reduce dripping; increased coverage of the nasal mucosa to maximise the area available for absorption, or the use of absorption enhancers to speed drug penetration2,3,4. The latter is somewhat controversial due to the risk of defeating the nose’s protective action against harmful inhaled antigens, pathogens or chemical toxins and few companies promoting this approach can support the high cost of demonstrating the safety of their proprietary excipients alone. A similar problem plagues companies who would enhance the solubility (and hence absorption rate or bioavailability) of an otherwise suspended drug through the use of solubility enhancing inclusion complexes (such as cyclodextrins), or phospholipids, polymer or surfactant based liposome, nanoparticle, nanocrystal or other molecular aggregates. While nasal delivery offers promise, it has been slower to demonstrate proof of concept in humans of ideas explored in animals. There are unique challenges extrapolating findings from a myriad of animal models – each with distinct anatomical and histological features, to humans. That said, some exciting possibilities have come to light.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Parkinson’s and Alzheimer’s diseases, plus brain cancers represent high value therapeutic opportunities potentially treatable via the nose – if it is possible to defeat the blood-brain barrier by taking advantage of the incomplete cribiform membrane that reportedly separates the CSF from the olfactory region of the nose. Debate rages about the applicability of animal models showing that anesthetics, chemotherapeutics, opiates and peptides reach the CSF faster than can be explained by diffusion across the BBB.
Vaccination
FluMist (MedImmune) has shown the viability of nasal vaccination, without the need for injection. If the immune response is stronger and/or longer lasting and provision of aseptic delivery less critical, the windfall opportunity presented by this season’s supply problems with injectable flu vaccine will raise the profile of nasal immunisation.
Sinus targeting
Historically, attempts to deliver nebulised aerosols into the sinuses have remained the province of off-label applications by ear, nose and throat specialists. Several recent studies have more formally attempted to document the delivery of drugs, via the nose, to the maxillary sinus through manipulation of droplet size or the use of pulsed pressure waves superimposed on the inhaled air stream. In general, delivery efficiency is low as demonstrated by in vitro models5, but the market for sinus delivery of decongestants, corticosteroids and antibiotics is large and certain to maintain the interest of several companies.
Fast onset
When rapid onset is required, but injection is unwarranted, the nose and lung are obvious targets. For example, a benzodiazepine nasal spray could be readily delivered in an emergency situation to an individual having a seizure. In some ways, smelling salts may have paved the way to inhaled treatments as diverse as erectile dysfunction and dypsnea. Bringing new products to the US market, be they new drugs or generic copies, has not been easy for would-be manufacturers – even for simple locally acting aqueous solutions. Several FDA guidance documents have highlighted the problems in demonstrating both bioavailability and bioequivalence for locally acting drugs6,7. In short, detecting small drug doses in the bloodstream is analytically challenging and provides little information about drug concentrations in specific regions of the nose. Inter-subject variability, compounded by uncertain breathing patterns and cyclic redistribution of inhaled air through either nostril every 3-4 hours8; and the unknown influence of head position, spray nozzle insertion angle or depth, on the ultimate site of deposition have forced evaluation of products based on a range of in vitro tests. While reducing anatomical or patient-induced inconsistency, the ability of droplet size, spray pattern and plume geometry results to predict the likelihood of equivalent efficacy has not been established (see Panel 1). The emergence of nasally administered suspension products, for which no test of dissolution behavior exists and the need to demonstrate specific regional deposition in the nose, will probably drive the need for new in vitro evaluation tools. Nasal scintigraphy has been used for several years to elucidate sites of initial deposition9 and, more recently, magnetic resonance imaging (MRI) is being used to generate the virtual geometry in which sophisticated computational fluid dynamics models attempt to predict deposition10. These theoretical models, together with cadaver or MRI-derived casts are providing new insights into where aerosol goes. Ultimately, to be useful, they must be validated and sophisticated enough to predict deposition in the olfactory region or sinuses, while providing an assurance that unintended pulmonary deposition is minimal. Until then, they remain confidence building tools that can guide a formulation or regulatory scientist, but not really prove anything. Such guidance is useful, however. The influence of those parameters that are impossible (due to cost or design complexity) to investigate in the clinic can be studied in silico or in vitro and new insights developed. Up until now, guesses (and they seem to have been just that) about how a patient should be instructed to use a nasal spray; what angle the tip should meet the nose, or what concentration of viscosity enhancing polymer should be incorporated, have prevailed. In the future we may have tools which allow rational selection of formulation excipients, based on their known impact on aerosolisation properties and site of deposition (see Panel 2). What will deliver such new drugs and formulations? The choice of nasal delivery device is based on many factors. Reliability, reproducibility, capability, ease of patient use, acceptability and, of course, cost. Recent product introductions have been mostly nasal sprays atomising aqueous formulations. These have evolved from being crude volumetric pumps susceptible to the vagaries of the way patients assembled and used them, into sophisticated, ready-to-spray devices able to perform reliably in the hands of most users (Figure 2) (see Panel 3). The most sophisticated among them can detect partial doses and have shapes that patients intuitively orient correctly prior to use. FluMist and Zomig, as shown in Figure 3, are early-adopters of sprayed unit dose technology that does not require chemical preservation – a concept that innovative manufacturers are now attempting to extend to multidose nasal products. A small number of companies have elected to retain nasal drops or reformulate pressurised nasal aerosol products using hydrofluoroalkanes11. The long-term popularity of the latter strategy remains to be seen – particularly if it impedes the transition from prescription-only to OTC as the product matures (perhaps due to concerns about increased, undesirable lung deposition). Nasally administered metered powders, while currently representing a small fraction of the market, may increase in popularity. The inherent stability of drugs in powder form, or the intriguing possibility of completely avoiding pulmonary deposition if DirectHalerTM Nasal (a unit dose powder inhaler in which a patient blows drug through a straw into their own nose as they exhale) becomes popular, suggests that powders may have an expanding role in nasal delivery. There seem to be numerous opportunities left to hit this most prominent of targets!
Acknowledgements
The authors would like to thank Pierre Carlotti and Laurence Peyronnet from Valois Pharmaceutical Division for their suggestions and permission to reproduce figures.
References
L. Illum. Is Nose-to-Brain Transport of Drugs in Man a Reality? Journal of Pharmacy and Pharmacology, 56: 3-17 (2004). A. K. Pennington et al. The Influence of Solution Viscosity on Nasal Spray Deposition and Clearance. International Journal of Pharmaceutics, 43: 221-224 (1988). K. H. G. Mills et al. Protective Levels of Diphtheria-Neutralizing Antibody Induced in Healthy Volunteers by Unilateral Priming-Boosting Intranasal Immunization Associated with Restricted Ipsilateral Mucosal Secretory Immunoglobulin A. Infection and Immunity, 71(2): 726-732 (2003). S. S. Davis et al. Absorption Enhancers for Nasal Drug Delivery. Clinical Pharmacokinetics, 42 (13): 1107-1128 (2003). A. Boehm et al. Investigating Drug Delivery to the Sinuses: An In Vitro Deposition Study Using a Nasal Cast Model. Respiratory Drug delivery IX, Davis Healthcare International Publishing, River Grove, Illinois (2004). Food Drug Administration. U.S. FDA Guidance for Industry, Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products-Chemistry, Manufacturing, and Controls Documentation, US Food and Drug Administration, Washington, DC (2002). Food Drug Administration. U.S. FDA Draft Guidance for Industry: Bioavailability and Bioequivalence studies for nasal aerosols and nasal sprays for local action, US Food and Drug Administration, Washington, DC (2003). R. Eccles. Nasal Airflow in Health and Disease. Acta Otolaryngology, 120: 580-595 (2000). J. D. Suman et al. Relevance of In Vitro Tests of Nasal Solutions to Predict In Vivo Deposition. Pharmaceutical Research, 19:1-6 (2002). J. S. Kimbell et al. Optimization of Nasal Delivery Devices Using Computational Models. Respiratory Drug delivery IX, Davis Healthcare International Publishing, River Grove, Illinois (2004).
Y. Guo. Improving Nasal Drug Delivery – An Investigation of Formulation Variables and Breathing Patterns on Aerosol Performance and Nasal Deposition Site. Dissertation, University of Maryland, Baltimore (2005). United States Pharmacopeia, Pharmacopeial Forum Vol. 30(4) [July-Aug. 2004], pp 1344-1345. G. Su, D. Farina, J. Langridge, K. Riehle, S. Somaraju & J. Suman. EFFECT OF ACTUATION PARAMETERS ON SPRAY WEIGHT, DROPLET SIZE, SPRAY PATTERN AND PLUME GEOMETRY FOR VISCOUS NASAL SPRAY FORMULATIONS, presented at Drug Delivery to the Lungs 15 Proceedings, London, UK, 2004.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.